Prolonged Grief Disorder Scale
- Introduced by
- Holly G. Prigerson, Paul K. Maciejewski
- Year
- 2008
- Type
- Self-report questionnaire
- Family
- diagnosis-focused-grief-assessment
What does it do?
The Prolonged Grief Disorder Scale (PG-13) is a 13-item diagnostic assessment tool developed by Prigerson and Maciejewski to operationalize the DSM-5-TR diagnostic criteria for Prolonged Grief Disorder.
Designed as a structured clinical instrument, the PG-13 directly maps onto the symptomatic, cognitive, and functional criteria required for diagnosis, making it invaluable in clinical and research settings where standardized diagnostic assessment is needed.
The intuition behind the method
Prolonged Grief Disorder (PGD), formalized in DSM-5-TR (2013) and ICD-11 (2022), represents a distinct mental health condition in which bereavement becomes pathological—characterized by persistent, intense yearning; preoccupation with the deceased; difficulty accepting death; emotional numbing; impaired role functioning; and social withdrawal that persists 12+ months post-loss (or 6+ months in the first year of bereavement if earlier assessment is clinically indicated). The PG-13 operationalizes these diagnostic criteria through targeted items, enabling clinicians to move beyond symptom severity assessment (as with the ICG) to formal diagnostic determination.
History
The PG-13 was developed in 2008 by Holly G. Prigerson and Paul K. Maciejewski following growing clinical and research recognition that persistent, impairing grief constitutes a distinct psychiatric condition. The scale directly reflects the operationalization of diagnostic criteria that were formalized in DSM-5-TR (published 2013) and ICD-11 (published 2022). As psychiatric taxonomy evolved to recognize Prolonged Grief Disorder as a distinct diagnosis, the PG-13 became the primary clinical tool for diagnostic determination. The scale has been translated into multiple languages and validated in dozens of studies confirming its diagnostic utility, sensitivity, and specificity across bereaved populations. It is now standard in grief-focused clinical trials and bereavement outcome research.
When to use it
The PG-13 is indicated for diagnostic evaluation of bereaved individuals presenting with prolonged, impairing grief symptoms, particularly in: psychiatric and psychological evaluation of complex bereavement cases; specialized grief clinics and bereavement counselling services; clinical research trials developing and testing Prolonged Grief Disorder treatments; forensic assessment (e.g., competency, criminal responsibility determinations requiring grief history); and stepped-care pathways for bereaved patients in primary care and emergency settings. Especially useful when clinical judgment alone is insufficient and a standardized, criterion-referenced diagnostic instrument is required.
Limitations and considerations
- Binary diagnostic output (present/absent) loses information about symptom severity variation; does not distinguish mild from severe Prolonged Grief Disorder or track treatment response as sensitively as continuous symptom scales.
- Requires clinician judgment regarding criterion interpretation (e.g., what constitutes 'functional impairment' or 'cultural departure'); less suitable for fully self-administered screening without clinical review.
- Time-dependent: DSM-5-TR criteria require symptom duration ≥12 months post-loss; the PG-13 cannot be meaningfully applied in acute grief (first 12 months), limiting early identification and early intervention.
- Limited cultural validation; DSM-5-TR criteria themselves reflect Western, individualistic grief norms; may misclassify normative grief expressions in collectivist cultures as pathological.
- Assumes death of human; limited applicability to anticipatory grief, loss of role, loss of identity, or non-death losses where some grief processes apply.
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Directly operationalizes DSM-5-TR Prolonged Grief Disorder diagnostic criteria, ensuring systematic and transparent diagnostic determination; improves diagnostic consistency across clinicians.
- Brief (13 items) and efficient; takes 5–10 minutes, allowing rapid diagnostic screening in time-pressured clinical settings.
- Criterion-referenced structure reduces subjective diagnostic impression; moves diagnosis from 'clinical feeling' to structured assessment.
- Extensively validated in diverse populations and cultural contexts; supported by large-scale epidemiological studies establishing diagnostic validity.
- Bridges research and clinical practice; same instrument can be used for case identification in research, clinical trials, and routine clinical care, enabling evidence-practice alignment.
Applications
- Diagnostic assessment in grief counselling and psychotherapy practices to confirm Prolonged Grief Disorder diagnosis and guide treatment planning.
- Clinical research and randomized controlled trials of grief-focused psychotherapies (Complicated Grief Therapy, Grief Monitoring and Processing, Acceptance and Commitment Therapy) to establish baseline diagnosis and confirm treatment efficacy.
- Epidemiological and public health research on prevalence, risk factors, and outcomes of Prolonged Grief Disorder in diverse populations.
- Training and supervision of mental health professionals, providing a structured framework for teaching diagnostic criteria and reliable diagnostic determination.
- Integration into stepped-care pathways in primary care, emergency psychiatry, and bereavement support services to identify individuals requiring specialist referral.
How it works
How it works
The PG-13 consists of 13 items that directly correspond to DSM-5-TR Prolonged Grief Disorder diagnostic criteria. Items assess core symptoms (yearning, intrusive thoughts, difficulty accepting death, trouble adjusting to loss) and functional impairment (role dysfunction, emotional numbing, withdrawal). Each item is rated on a scale reflecting symptom presence and severity, typically ranging from 0 (not present) to 4 (very often). The scale requires 5–10 minutes for self-report completion. Administration presupposes that 12+ months have elapsed since death (or 6+ months in specific circumstances); clinicians confirm this timeline before administration.
Formula
Administer 13 items assessing DSM-5-TR Prolonged Grief Disorder criteria
The PG-13 is scored by determining whether the respondent meets the full DSM-5-TR diagnostic criteria cluster: (1) core grief symptom (yearning/preoccupation), (2) cognitive/emotional symptoms (≥4 of 8 specified symptoms), (3) functional impairment, (4) symptom duration (≥1 year), and (5) distress severity. Rather than a continuous score, the PG-13 yields a binary diagnostic determination: Prolonged Grief Disorder present (meets all criteria) or absent (does not meet all criteria). Some modified versions calculate total symptom counts for research purposes; see specific study protocols.
Formula
Determine presence or absence of diagnostic criteria based on symptom endorsement and duration
Diagnostic interpretation is criterion-referenced: if all DSM-5-TR PGD criteria are met, Prolonged Grief Disorder is diagnosed. Clinical interpretation also considers: (1) symptom onset relative to death (should emerge within first 12 months but not necessarily immediately); (2) severity and functional impact (must cause clinically significant distress and impair work, social, or daily functioning); (3) differential diagnosis (symptoms not attributable to another psychiatric disorder, substance use, or medical condition); (4) cultural context (grief expression varies; diagnosis requires that symptoms represent departure from cultural norms).
Formula
Interpret as diagnostic assessment tool; presence of criterion cluster indicates Prolonged Grief Disorder
Common pitfalls
- Misapplying the 12-month rule: assuming that any grief symptoms present at 12+ months indicate Prolonged Grief Disorder; must confirm symptom onset within 12 months post-loss AND persistence, not new onset after 12 months.
- Over-relying on the PG-13 without clinical assessment of context (manner of death, concurrent stressors, cultural factors, prior trauma, psychiatric history); a 'positive' PG-13 is diagnostic suggestion, not diagnosis; clinical judgment is essential.
- Administering the PG-13 in acute grief (<6–12 months) and misinterpreting normal acute grief as Prolonged Grief Disorder; the DSM-5-TR allows earlier diagnosis (6 months) only in specific circumstances requiring clinical justification.
- Failing to assess and rule out competing diagnoses (Major Depressive Disorder, PTSD from manner of death, substance use disorder); PGD diagnosis requires that symptoms are not better explained by another condition.
- Using PG-13 as the sole outcome measure in treatment trials without capturing symptom-level change; use continuous scales (ICG, TRIG) alongside PG-13 for treatment monitoring.
Frequently asked questions
How does the PG-13 differ from the ICG?
The ICG (19 items, continuous score 0–76) measures complicated grief symptom severity and is used for screening and outcome measurement; a cutoff of ≥25 suggests complicated grief, but diagnosis requires clinical judgment. The PG-13 (13 items) directly operationalizes DSM-5-TR diagnostic criteria and yields a binary diagnostic determination (Prolonged Grief Disorder present/absent). In practice, the ICG is used for symptom screening and treatment monitoring, while the PG-13 is used for formal diagnostic assessment.
Can the PG-13 be used before 12 months post-loss?
DSM-5-TR generally requires ≥12 months duration for Prolonged Grief Disorder diagnosis. However, earlier diagnosis (6–12 months post-loss) is permitted if symptoms are clearly excessive and cause significant impairment beyond what is expected in the first year of bereavement. The PG-13 can be administered at any time to assess symptom presence, but diagnostic determination typically awaits 12+ months unless clinical circumstances warrant earlier assessment.
Is the PG-13 copyrighted or available for clinical use?
The PG-13 is published in peer-reviewed literature and is available for clinical and research use. No licensing fee or permission is typically required for use in clinical practice or academic research. Clinicians should cite the original source (Prigerson & Maciejewski, 2008 or later validation studies) and confirm that their use aligns with institutional review board (IRB) or ethics committee requirements.
Can the PG-13 be used to monitor treatment response over time?
The PG-13's binary diagnostic structure (present/absent) is less sensitive to symptom-level change during treatment; a patient may remain 'PG-13 positive' while showing significant improvement in individual symptoms. For monitoring treatment response, continuous measures like the ICG (which can show score reductions during therapy) are more appropriate. The PG-13 is best used at baseline to confirm diagnosis and at endpoint to assess diagnostic remission; use symptom severity scales for progress monitoring.
Related methods
Sources
Prigerson, H. G., & Maciejewski, P. K. (2008). Prolonged grief disorder: Defining the disorder and addressing its clinical and public health significance. Psychotherapy and Psychosomatics, 77(6), 365–376.
Open publication referenceCopied.